Insmed

Insmed Net Debt

The Net Debt of Insmed (INSM) as of Nov 2, 2026 is -869.82 M USD. In the previous year, Net Debt was -142.35 M USD — a change of 511.03% (lower).

Net Debt

-869.82 MUSD

YoY

511.03%

Last updated:

Net Debt of Insmed is 2025 -869.82 M USD. Net Debt of Insmed was 2024 -142.35 M USD. It decreases by 511.03% lower compared to the previous year.

The Insmed Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2018
-178.47 M USD
Jan 1, 2019
-130.73 M USD
Jan 1, 2020
-160.66 M USD
Jan 1, 2021
-135.48 M USD
Jan 1, 2022
7.82 M USD
Jan 1, 2023
559.54 M USD
Jan 1, 2024
-142.35 M USD
Jan 1, 2025
-869.82 M USD
The Insmed Net Debt history
YEARNet DebtYoY
-869.82 MUSD+511.03%
-142.35 MUSD-125.44%
559.54 MUSD+7,055.19%
7.82 MUSD-105.77%
-135.48 MUSD-15.67%
-160.66 MUSD+22.89%
-130.73 MUSD-26.75%
-178.47 MUSD-45.18%
-325.57 MUSD+202.03%
-107.79 MUSD-58.18%
-257.78 MUSD+91.90%
-134.33 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Insmed Stock analysis

What does Insmed do? Insmed Inc is a biopharmaceutical company that was founded in Virginia in 1999 by Dr. Melvin Sharoky. The company specializes in researching, developing, and marketing therapies for rare and serious lung diseases and immune system disorders. Insmed's business model is based on a solid scientific foundation and has a broad network of experienced researchers and clinical experts. The company aims to develop innovative therapies for unmet medical needs in the market. Insmed focuses on the treatment of niche diseases and related medical needs. The company is divided into two divisions: lung diseases and immunology. The lung diseases division includes the drug ARIKAYCE®, which was developed for patients with a specific form of pneumonia called very severe persistent Mycobacterium avium complex lung disease (vPSMAC). ARIKAYCE® is the first approved drug for this type of lung disease. In addition, Insmed is working on the development of therapies for other lung diseases such as non-tuberculous mycobacterial (NTM) lung disease and bronchiectasis. Insmed's immunology division focuses on the development of therapies for rare immune disorders such as autoinflammatory diseases (AID) and respiratory allergies. Insmed recently developed a drug called Bautista™, which focuses on the treatment of NLRC4 deficiency, a very rare and serious genetic disease. Insmed is constantly working to advance its science in order to develop new and innovative therapies for rare diseases. The company makes significant investments in research and development, which is a key pillar of its business success. In 2018, the company received approval for ARIKAYCE® from the US Food and Drug Administration (FDA), leading to a successful market entry. Insmed is also actively working with regulatory authorities in Europe and Asia to obtain approval for ARIKAYCE® and increase international distribution. Today, Insmed is a globally operating company that has a broad impact on the healthcare industry. It believes in its scientific expertise and works hard to develop innovative therapies to help patients with rarer disease conditions achieve a better quality of life. Insmed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Insmed stock

Net Debt of Insmed is -869.82 M USD in 2025.

Net Debt of Insmed changed from -142.35 M USD to -869.82 M USD, representing a 511.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt Insmed since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's Insmed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Insmed

All Key Metrics — Insmed